This study was designed to investigate whether mineral trioxide aggregate (MTA) Fillapex®, an MTA/salicylate-based endodontic sealer, exerts cytotoxic and toxicogenomic effects on human gingival fibroblasts (HGFs). HGFs were exposed to MTA Fillapex® at concentrations of 5%, 10%, 20%, and 40% for 24 h. Cytotoxicity, cell survival (5 days), cell cycle kinetics (flow cytometry), genotoxicity (comet assay), and gene (, , and ) expression profiles were evaluated using reverse-transcriptase quantitative polymerase chain reaction. MTA Fillapex® was cytotoxic to HGFs at the two highest concentrations (20% and 40%), and cell survival decreased after 5 days treatment only with 40% concentration. After MTA Fillapex® treatment, there was an increase in the expression of apoptosis-related genes , , and , but no increase in DNA damage. Cement also induced changes in cell cycle kinetics, apoptosis, and necrosis rates. The data show the ability of MTA Fillapex® endodontic sealer to induce cellular and genetic alterations in HGFs. Our findings suggest that this compound should be used with caution to avoid health-related risks to the buccal tissue.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742916 | PMC |
http://dx.doi.org/10.1016/j.toxrep.2022.05.004 | DOI Listing |
Materials (Basel)
December 2024
Department of Advanced General Dentistry, College of Dentistry, Yonsei University, Seoul 03722, Republic of Korea.
With the advent of bioceramic sealers, sealers have become a more important filling material for endodontic treatment. When a solid sealer, rather than an elastic gutta-percha, occupies a significant portion of the root canal, it is unclear whether the tooth structure will be strengthened to withstand stress or whether the increased stiffness will transmit the load directly to the entire root, potentially causing root fracture. This study compared the fracture resistance and fracture patterns of roots filled with various root canal sealers, including bioceramic sealers, and each corresponding filling technique.
View Article and Find Full Text PDFBr J Clin Pharmacol
January 2025
Department of Drug Science and Technology, University of Turin, Turin, Italy.
Aims: In Europe, the European Medicines Agency (EMA) has an accelerated pathway to prioritize approval of medicines. Approved drugs are then assessed by Health Technology Assessment (HTA) bodies before being made available to patients. The aim of the study was to evaluate the characteristics of the drugs admitted to the EMA accelerated assessment (AA) and scrutinize the downstream HTA procedures regarding these medicines and the final assessment regarding added therapeutic value (ATV).
View Article and Find Full Text PDFBDJ Open
January 2025
Oral Radiology, Faculty of Dentistry, Cairo University, Giza, Egypt.
Aim: Clinical and radiographic evaluation of SDF versus MTA as indirect pulp capping agents in deeply carious first permanent molars.
Methodology: This study was conducted on (30) first permanent molars indicated for indirect pulp capping (IPC) randomly allocated to either SDF or MTA groups (n = 15). The molars were finally restored with glass hybrid glass ionomer restoration.
Biochim Biophys Acta Mol Cell Biol Lipids
January 2025
Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Khandwa Road, Simrol, Madhya Pradesh 453552, India. Electronic address:
DHHC-mediated protein-S-palmitoylation is recognized as a distinct and reversible lipid modification, playing a pivotal role in the progression and prevention of multiple diseases, including cancer and neurodegenerative disorders. Over the past decade, growing evidence indicates the crucial role of DHHC2 in preventing tumorigenesis by palmitoylation of various protein substrates. However, a comprehensive understanding of the specific impact of DHHC2 on cancer cell metabolic regulation remains unclear.
View Article and Find Full Text PDFJ Med Chem
January 2025
Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
Protein arginine methyltransferase 5 (PRMT5), which catalyzes the symmetric dimethylation of arginine residues on target proteins, plays a critical role in gene expression regulation, RNA processing, and signal transduction. Aberrant PRMT5 activity has been implicated in cancers and other diseases, making it a potential therapeutic target. Here, we report the discovery of a methylthioadenosine (MTA) cooperative PRMT5 inhibitor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!